Amicus Aims to Expand Rare and Intractable Disease Pipeline in Japan

Amicus Japan President Kurt Rimkus Amicus Therapeutics, which entered the Japanese market with the launch of the oral Fabry disease treatment Galafold (migalastat) in May, plans to expand its development pipeline in Japan in the fields of rare and intractable...read more